Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

Improved drug delivery and compound identification with the Cellaxess technology

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be presenting new data at Neuroscience 2013, 9-13 November, San Diego (USA). In a series of poster presentations, Cellectricon (booth #933) will demonstrate how its technology can be applied effectively for drug discovery, particularly in relation to cytoskeletal disorders and neurodegenerative diseases. Cellectricon’s novel approach is based around electric field stimulation, and the posters, which include primary data, detail how the Cellaxess technology can be used to deliver pharmacologically active molecules to neuronal cultures without compromising cell viability or functionality. The poster session will also reveal an assay for the high-throughput identification of compounds that modulate neuronal excitability. In this way, attendees will be shown how compound characterization and data-based decision making can be achieved early in a project life-cycle, reducing unnecessary time and cost.

The poster presentations take place on 11-13 November, and Cellectricon employees will be on-hand to answer any questions you may have during this time. Please visit the Cellectricon website for more information on the content of the posters, or follow the links below. Cellectricon will also be exhibiting at booth #933, so drop by to learn more about Cellectricon’s Discovery Services, launched earlier this year.

Small Molecule Delivery into primary neuronal cells capillary-electrode Electroporation  Monday 11 Nov, 10-11am

A method for patch-clamp recordings of fast-acting ion channels in rat dorsal root ganglion cells  Tuesday 12 Nov, 11-12am

Characterization of the subpopulation of neurons responding in an electric field stimulation assay   Wednesday 13 Nov, 2-3pm

Development of a high throughput electric field stimulation assay for identification of compounds modulating excitability in sensory neurons Wednesday 13 Nov, 4-5pm

Source: http://www.cellectricon.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cellectricon. (2013, October 31). Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20131031/Cellectricon-to-demonstrate-Cellaxess-technology-at-Neuroscience-2013.aspx.

  • MLA

    Cellectricon. "Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20131031/Cellectricon-to-demonstrate-Cellaxess-technology-at-Neuroscience-2013.aspx>.

  • Chicago

    Cellectricon. "Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013". News-Medical. https://www.news-medical.net/news/20131031/Cellectricon-to-demonstrate-Cellaxess-technology-at-Neuroscience-2013.aspx. (accessed April 24, 2024).

  • Harvard

    Cellectricon. 2013. Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20131031/Cellectricon-to-demonstrate-Cellaxess-technology-at-Neuroscience-2013.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement